Unique ID issued by UMIN | UMIN000041452 |
---|---|
Receipt number | R000046899 |
Scientific Title | Estimation of cost value based on the convenience of an anti-influenza agent baloxavir marboxil |
Date of disclosure of the study information | 2020/08/18 |
Last modified on | 2022/02/22 16:16:39 |
Estimation of cost value based on the convenience of an anti-influenza agent baloxavir marboxil
Estimation of cost value based on the convenience of an anti-influenza agent baloxavir marboxil
Estimation of cost value based on the convenience of an anti-influenza agent baloxavir marboxil
Estimation of cost value based on the convenience of an anti-influenza agent baloxavir marboxil
Japan |
influenza
Infectious disease |
Others
NO
To estimate the monetary value of convenience of an influenza drug baloxavir marboxil, which is taken orally and one time, for patients, particularly considering the route and frequency of administration.
Others
convenience
Convenience of drugs: route, frequency, and duration of administration, and out-of-pocket expenses
Others,meta-analysis etc
20 | years-old | <= |
64 | years-old | >= |
Male and Female
Individuals who were prescribed any influenza drugs (oral or inhalation) last season (from October 2018 to April 2019) or this season (from October 2019 to the present)
N/A
3000
1st name | Shinzo |
Middle name | |
Last name | Hiroi |
Shionogi & CO., LTD.
Medical Affairs Dept.
530-0012
1-1-4, Shibata, Kita-ku Osaka
06-6485-5201
shinzo.hiroi@shionogi.co.jp
1st name | Akira |
Middle name | |
Last name | Yokomasu |
Shionogi & CO., LTD.
Medical Affairs Dept.
530-0012
1-1-4, Shibata, Kita-ku Osaka
06-6485-5201
akira.yokomasu@shionogi.co.jp
Shionogi & CO., LTD.
Shionogi & CO., LTD.
Profit organization
RIHDS Ethical Review Board
12th Floor, Suitomo Shiba Daimon Building, 2-5-5 Shiba Daimon, Minato-ku, Tokyo, Japan
03-5733-5010
rihds@jmdc.co.jp
NO
2020 | Year | 08 | Month | 18 | Day |
N/A
Published
https://www.tandfonline.com/doi/full/10.1080/13696998.2021.1877150
3137
The monetary value for oral antivirals was estimated to be higher, saving JPY 741 (USD 7.06, as of August 2020), compared with inhalant. Regarding the length and frequency of administration, five days corresponds to an increase of JPY 2,072, compared with one day, and twice a day corresponds to a JPY 574 increase compared to once a day.
2022 | Year | 02 | Month | 22 | Day |
2021 | Year | 02 | Month | 12 | Day |
Individuals who were prescribed any influenz
a drugs (oral or inhalation) last season (fr
om October 2018 to April 2019) or this seaso
n (from October 2019 to the present)
We used an online panel managed by research company for the online survey. The respondents were selected by screening questions.
N/A
Convenience of drugs: route, frequency, and
duration of administration). The values were converted as montetary values based on the utility of out-of-pocket expenses.
Completed
2020 | Year | 07 | Month | 20 | Day |
2020 | Year | 08 | Month | 18 | Day |
2020 | Year | 08 | Month | 18 | Day |
2020 | Year | 08 | Month | 31 | Day |
A questionnaire survey will be performed for the eligible individuals in research panel in a research company.
The results of survey will be analyzed by conjoint analysis.
2020 | Year | 08 | Month | 18 | Day |
2022 | Year | 02 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046899
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |